Oregon Drug Use Review / Pharmacy & Therapeutics Committee
Thursday, November 29, 2018 1:00 - 5:00 PM
HP Conference Room
4070 27th Ct. SE
Salem, OR 97302

MEETING AGENDA

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9).

I. CALL TO ORDER

1:00 PM
A. Roll Call & Introductions
R. Citron (OSU)
B. Conflict of Interest Declaration
R. Citron (OSU)
C. Approval of Agenda and Minutes
T. Klein (Chair)
D. Department Update
T. Douglass (OHA)
E. Legislative Update
T. Douglass (OHA)

1:10 PM
II. CONSENT AGENDA TOPICS
T. Klein (Chair)

A. Long-Acting Insulins DERP Summary
B. Humira® (adalimumab) Indication Review for Hidradenitis Suppurativa
C. Quarterly Utilization Reports
1. Public Comment

III. DUR ACTIVITIES

1:15 PM
A. ProDUR Report
R. Holsapple (DXC)
B. RetroDUR Report
D. Engen (OSU)
C. Oregon State Drug Reviews
K. Sentena (OSU)
1. Update on Treatment Options for Moderate to Severe Atopic Dermatitis
2. Management Strategies for Patients with Prediabetes

IV. PREFERRED DRUG LIST NEW BUSINESS

1:30 PM
A. Severe Acne Class Review
J. Page (OSU)
1. Class Review/Prior Authorization Criteria
2. Public Comment
3. Discussion of Clinical Recommendations to OHA
1:50 PM  B. Hepatitis C Direct Acting Antivirals Policy Discussion
         1. Public Health Response to HCV in Oregon: Need for Screening and Treatment
         2. Prior Authorization Criteria
         3. Public Comment
         4. Discussion of Clinical Recommendations to OHA

2:20 PM  C. Orilissa™ (elagolix) New Drug Evaluation
         1. New Drug Evaluation/Prior Authorization Criteria
         2. Public Comment
         3. Discussion of Clinical Recommendations to OHA

V. DUR OLD BUSINESS

2:35 PM  A. Nusinersen: OHA SMARTEN Participation
         1. OHA SMARTEN Participation/Prior Authorization Criteria
         2. Public Comment
         3. Discussion of Clinical Recommendations to OHA

2:55 PM  B. Growth Hormone Prior Authorization Criteria Update
         1. Prior Authorization Criteria
         2. Public Comment
         3. Discussion of Clinical Recommendations to OHA

3:05 PM  BREAK

3:15 PM  C. Testosterone Prior Authorization Criteria Update
         1. Prior Authorization Criteria
         2. Public Comment
         3. Discussion of Clinical Recommendations to OHA

VI. DUR NEW BUSINESS

3:15 PM  A. Substance Use Disorder Class Update/Drug Use Evaluation
         1. Class Update/Prior Authorization Criteria
         2. Lucemyra™ (lofexidine hydrochloride) New Drug Evaluation
         3. Drug Use Evaluation
         4. Public Comment
         5. Discussion of Clinical Recommendations to OHA

3:55 PM  VII. EXECUTIVE SESSION

4:50 PM  VIII. RECONVENE for PUBLIC RECOMMENDATIONS

IX. ADJOURN